Consensus AtriCure, Inc.

Stocks

ATRC

US04963C2098

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq 04:00:00 15/09/2026 HKT			5-day change	1st Jan Change
55.79 ^USD	+2.29%		+8.29%	+41.03%

09-04	Atricure Insider Sold Shares Worth $407,558, According to a Recent SEC Filing	MT
09-02	Needham Raises Price Target on AtriCure to $64 From $45, Keeps Buy Rating	MT

Evolution of the Average Target: AtriCure, Inc.

Evolution of the Target Price: AtriCure, Inc.

Changes in Analyst Recommendations: AtriCure, Inc.

b2094aeb4c61ea.LV12aas63VfzRFcnGfbNhxs1epLrO3htIgnrwiuEYvw.eBpBL8hAqiTBCxZVK6ynxTZPIqKGXzE-Wz3dqmPyFJt9CgNb3n6eBL0jJA~fc053bc65a11a94e6eba1ea7f698f4f3

Analysts' recommendations: AtriCure, Inc.

09-02	Needham Raises Price Target on AtriCure to $64 From $45, Keeps Buy Rating	MT
07-28	UBS Adjusts Price Target on AtriCure to $50 From $55, Maintains Buy Rating	MT
02-19	UBS Adjusts AtriCure Price Target to $55 From $60, Maintains Buy Rating	MT
02-18	Oppenheimer Downgrades AtriCure to Market Perform From Outperform	MT
02-12	AtriCure Shares Fall After JPMorgan Downgrade	MT
02-12	Top Midday Decliners	MT
02-11	JPMorgan Downgrades AtriCure to Neutral From Overweight, Adjusts PT to $36 From $48	MT
30/07/25	Needham Raises Price Target on AtriCure to $45 From $44, Keeps Buy Rating	MT
30/07/25	AtriCure Q2 revenue beats estimates	RE
30/04/25	UBS Adjusts Price Target on AtriCure to $58 From $60, Maintains Buy Rating	MT
28/03/25	Canaccord Genuity Adjusts Price Target on AtriCure to $52 From $66, Maintains Buy Rating	MT
13/02/25	Oppenheimer Adjusts AtriCure Price Target to $45 From $36, Maintains Outperform Rating	MT
30/10/24	UBS Adjusts Price Target on AtriCure to $40 From $35, Maintains Buy Rating	MT
31/07/24	Needham Adjusts AtriCure's Price Target to $34 From $40, Keeps Buy Rating	MT
02/05/24	Needham Lowers AtriCure's PT to $40 From $46 Due to Peer Multiple Contraction, Keeps Buy Rating	MT
23/04/24	Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32	MT
16/02/24	UBS Adjusts AtriCure Price Target to $58 From $57, Maintains Buy Rating	MT
16/02/24	Stifel Adjusts Price Target on AtriCure to $42 From $50, Maintains Buy Rating	MT
16/02/24	Needham Adjusts Price Target on AtriCure to $46 From $44, Keeps Buy Rating	MT
23/01/24	UBS Adjusts AtriCure Price Target to $57 From $56, Maintains Buy Rating	MT
23/10/23	JMP Securities Initiates AtriCure With Market Outperform Rating, Price Target is $60	MT
29/09/23	UBS Initiates AtriCure With Buy Rating, Price Target is $56	MT
26/07/23	Needham Adjusts Price Target on AtriCure to $68 From $60, Maintains Buy Rating	MT
03/05/23	Needham Adjusts Price Target on AtriCure to $60 From $58, Maintains Buy Rating	MT
23/02/23	BTIG Lowers Price Target on AtriCure to $55 From $65, Maintains Buy Rating	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ATRICURE, INC.					-7.39%
	ABBOTT LABORATORIES					+16.66%
	MEDTRONIC PLC					+11.76%
	CENCORA, INC.					+13.7%
	HOYA CORPORATION					+36.42%
	BECTON, DICKINSON AND COMPANY					+6.97%
	DEXCOM, INC.					+11.15%
	MEDLINE INC.					+36.85%
	WEST PHARMACEUTICAL SERVICES, INC.					+14.13%
	TERUMO CORPORATION					+38.82%
	Average					+17.91%
	Weighted average by Cap.					+17.46%